IBRANCE GLOBAL MARKETING, DIRECTOR, HER2+ Indication Launch (Secondment - 12 Months)
This job is no longer available
There are still lots of open positions. Let's find the one that's right for you.
About The Position
At Pfizer Oncology, we are committed to advancing transformative medicines wherever we can make a profound difference on the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of approved cancer medicines including breast, prostate, kidney, lung, and hematology. IBRANCE (palbociclib) is the first-in-class CDK 4/6 inhibitor that helped transform the treatment of HR-positive HER2-negative (HR+, HER2-) metastatic breast cancer (mBC) following its initial approval in the US in February 2015. Now, 10 years later, it has received regulatory approval in more than 100 countries and continues to impact patients’ lives, with over 838,000 patients treated with IBRANCE worldwide. In 2025, IBRANCE is set to expand its reach to HR-positive HER2-positive (HR+, HER2+) mBC patients with the pending approval of a first-line maintenance indication, which represents a strategic opportunity to differentiate IBRANCE and elevate its leadership in HR+ mBC. The PATINA study, a Phase 3 trial, showed that adding IBRANCE to standard-of-care therapy significantly extended progression-free survival by approximately 15 months. These breakthrough results could position IBRANCE as the first and only CDK4/6i indicated in the HR+/HER2+ 1L maintenance mBC setting, reinforcing the brand’s presence and value.
